

4. The patient view on the ERN programme: Share, care, cure, and pathways

Dalia Aminoff, Rita Serena Bartezzi, Nicole Schwarzer, Claire Harkin, Kate Tyler, Anna De Santis, John Osborne, Kenneth Manzie, and Robert Cornes

European Reference Networks: Advancing care and treatments for those born with rare and complex diseases	31
Establishing best practice—Caring and collaboration	31
The role of European Patient Advocacy Groups	32
Centralisation of care in rare diseases and complex conditions	33
Adapting to a different life	34
Rare diseases and complex conditions—A lifelong challenge	34
Puberty	34
Promoting Independence	35
Facing the challenges of rare diseases and complex conditions – The example of living with anorectal malformation	35
Clinicians and therapeutic staff	35
Holistic care	36
A collaborative approach	36
Rare diseases and complex conditions—A late diagnosis: The real story of the psychological impact of KS/XXY	36
Promoting excellent communication	37
References	38

5. Cross-ERN actions and collaborations by ERN eUROGEN

Michelle Battye, Matthew Bolz-Johnson, and Jen Tidman

Introduction and background	39
Unique needs of rare diseases	39
Need for centralisation and collaboration globally	39
ERN maturing capacities and experience	40
Policy context	40
European policy	40
Global policy	40
Cross-ERN collaboration	40
Cross-ERN working groups	40
European rare disease research coordination and support action (ERICA)	40

Collaboration with individual ERNs	41
European collaboration	42
Supporting partners: Organisations and individual experts	42
Rare 2030	44
European Joint Programme on Rare Diseases (EJP RD)	44
Other	45
Global collaboration	45
Global network for rare diseases (GNRD)	45
CureforU	45
Murdoch Children's Research Institute in Melbourne, Australia	46
Confederación Americana de Urología (CAU)	46
Ukraine	46
Opportunities	47
Expansion of collaboration in the WHO European region/outside the EU	47
Taking part in the pilot global network for rare diseases (GNRD)	47
References	47

6. Development of the ERN eUROGEN registry

Loes F.M. van der Zanden, Isabel C. Hageman, Lotte Boormans, Loes Oomen, and Wim P.J. Witjes

Introduction	49
Objectives	49
Data elements and data collection	49
Registry setup	51
Centralised registry	51
Participating HCPs	51
Informed consent	51
Prospective and retrospective inclusion	51
Data 'ownership'	51
Roles	52
Access to the ERN eUROGEN registry	52
Finances	53
Data analyses	53
Quality aspects	54
Information quality	54
Data quality evaluation	54
Quality audit visits	55
Example of the potential use of the registry	55
Acknowledgments	57
References	57

7. Development of ERN eUROGEN clinical practice guidelines (CPGs) and clinical decision support tools (CDSTs)

Jen Tidman, Wouter F.J. Feitz, Ramnath Subramaniam, Dalia Aminoff, Juan Antonio Blasco-Amaro, Beatriz Carmona-Hidalgo, Lourdes González-Bermúdez, Carmen Martín-Gómez, Elena Stallings, María José Vicente-Edo, and Patricia Gavín Benavent

Introduction and background	59
Clinical practice guidelines and clinical support decision tools: Definitions and disclaimers	59
ERN eUROGEN and guidelines	59
ERN guidelines consortium	60
Background and formation	60
Training on guidelines	61
How the consortium and ERN eUROGEN work together	62
ERN Eurogen Guidelines Expert Panel	63
ERN Eurogen Guidelines work and collaborations	64
Bladder exstrophy/epispadias (EA 1.2)	64
Rare urological stone and kidney diseases (EA 1.3)	64
Nonsyndromic urogenital tract malformations (EA 1.4)	64
Posterior urethral valves (EA 1.5)	65
Urorectal/anorectal malformations (EA 1.7)	65
Rare diseases and conditions affecting the female urethra (EA 2.2)	66
Interstitial cystitis (EA 2.5)	66
Penile cancer (EA 3.1)	66
Adrenal tumours (EA 3.3)	67
Future objectives	67
Acknowledgments	67
References	67

Part III Clinical chapters

Section A Workstream 1: Rare congenital uro-recto-genital anomalies

8. Expertise Area 1.1: Complex genital reconstructions in patients with differences of sex development

Verena Ellerkamp, Katja P. Wolffenbuttel, and Raimund Stein

Overview/DSD classification	73
Diagnostics	73
Recommended age at surgery and legislation	75
Surgical concepts of complex genital reconstruction	75
Feminising genitoplasties	75
Masculinising genitoplasties	76
Aspects of gonadal surgery	78
Surgical management of gonadal dysgenesis	78
References	79

9. Expertise Area 1.2: Bladder exstrophy/epispadias

Gundela Holmdahl, Marc-David Leclair, Wolfgang H. Rösch, and Alaa El-Ghoneimi

Epidemiology	84
Types and variants	84
Surgical management: Two current surgical strategies	87
German strategy and experience, the staged approach	87
The Nantes one-stage combined delayed bladder closure with Kelly radical soft-tissue mobilisation (RSTM)	89
Long-term results after bladder exstrophy repair	90
References	93

10. Expertise Area 1.3: Rare urological stones and kidney diseases

Matthieu Peycelon, Annabel Paye-Jaouen, Delphine Demede, Valeska Bidault, Marie Andersson, and Anne-Françoise Spinoit

Introduction	97
Epidemiology	97
Composition	97
Tests	98
Metabolic evaluation	98
Imaging	98
Aetiologies	98
Infectious calculi	98
Calculi secondary to lifestyle	98
Calcium calculi and hypercalciuria	99
Cystinuria	99
Distal tubular acidosis	99
Hyperoxaluria	100
Uric acid calculi	100
Management	101
Medical care	101
Urological management	102
Conclusion	103
References	104

11. Expertise Area 1.4: Nonsyndromic urogenital tract malformation (neurogenic bladder and spina bifida)

Giovanni Mosiello, Rien Nijman, Christian Radmayr, Michaela Dellenmark-Blom, Sylvia Roozen, Jean Marie Jouannic, Raimund Stein, and Kate Abrahamsson

Introduction	107
Background	107
Classification	108
Neurological pathologies affecting the LUT	108
Spinal dysraphism	108
Tethered cord	108
Sacral agenesis and anorectal malformations	110
Other neurological lesions	110
Severe voiding dysfunction or nonneurogenic neurogenic bladder	111
Diagnostic evaluation	111
Physical and neurological exam	111
Voiding diaries, pad tests, and questionnaires	111
Urinalysis and PVR	111

Investigations	111
Noninvasive urodynamics	111
Ultrasonography	112
Urodynamics and videourodynamics	112
EMG	114
Evaluation of neuropathic bowel dysfunction	114
Urethrocystoscopy	114
Renal function evaluation	114
Neuro-imaging	114
Other electrophysiological studies	116
Clinical approach	117
Management of neurogenic bladder in children	117
Prenatal management and foetal surgery	117
Postnatal management	117
First-line management of neurogenic bladder	118
Neurogenic bowel management	120
Urinary tract infection management	121
Sexuality and fertility	121
Surgery for continence	121
Follow-up evaluation	122
Conclusions	123
References	124

12. Expertise Area 1.5: Posterior urethral valves

Yazan F. Rawashdeh, Magdalena Fossum, Raimund Stein, and Rafal Chrzan

Definition	129
Embryology	129
Epidemiology	130
Genetics	130
Pathophysiology	130
Bladder function and vesicourethral reflux	130
Upper tracts	131
Potter syndrome	131
Lungs	131
Antenatal diagnosis	132
Antenatal management	132
Immediate postnatal management	133
Diversion	133
Ablation	133
Other surgical interventions	133
Bladder neck incision	133
Circumcision	134
Medical interventions	134
Anticholinergics	134
Alpha-Blockers	134
Prophylaxis	134

Vesicovaginal and Vesicorectal fistulae	176	Other treatments	200
Vesicovaginal fistulae	176	Congenital urethral malformations (e.g. proximal hypospadias)	200
Vesicorectal fistulae/rectourethral fistulae	177	Aetiology and incidence	200
References	178	Diagnostics	200
		How to treat	200
16. Expertise Area 2.2: Rare diseases and conditions affecting the female urethra		Future perspective: Tissue engineering?	200
		References	201
<i>José Medina-Polo, Malte W. Vetterlein, and Jakob Klemm</i>			
Introduction and epidemiology	183	18. Expertise Area 2.4: Rare retroperitoneal diseases and conditions	
Urethral stricture	183		
Aetiology and pathophysiology	183	<i>Maria Virginia Amesty, Susana Rivas, Fabrizio Dal Moro, and Mariangela Mancini</i>	
Symptoms and signs	184	Hydronephrosis	205
Diagnostic evaluation	184	Upper urinary tract obstruction	205
Differential diagnoses	185	Ureteropelvic junction obstruction (UPJO)	205
Disease management	186	Epidemiology and aetiology	205
Urinary fistula	188	Natural history of obstruction of the pyeloureteral junction	206
Aetiology and pathophysiology	188	Diagnosis	208
Symptoms and signs	189	Diagnostic algorithm of UTD with suspected UPJO	212
Diagnostic evaluation	189	Surgical treatment of OPU	214
Differential diagnosis	190	Primary obstructive megaureter	216
Disease management	190	Classification of megaureteres	216
References	192	Diagnosis	216
		Natural history of the primary megaureter without reflux	218
17. Expertise Area 2.3: Urethral reconstruction in rare diseases and complex conditions		Algorithm for management of nonrefluxing primary megaureter	218
		Surgical treatment of primary obstructive megaureter	219
<i>Malte W. Vetterlein, Michel I.A. Wyndaele, Felix Campos-Juanatey, Jakob Klemm, Laetitia M.O. de Kort, Margit Fisch, Petra de Graaf, Tim Brits, and Gunter De Win</i>		Other rare retroperitoneal conditions	221
Introduction	195	Nutcracker syndrome	221
Difficult strictures in otherwise healthy urethra	195	Retrocaval ureter	222
Pelvic fracture-associated posterior urethral injury	195	Retroperitoneal fibrosis	222
Difficult strictures in the diseased urethra	196	References	226
Lichen Sclerosus	196		
Amyloidosis	197	19. Expertise Area 2.5: Bladder pain syndrome/Interstitial cystitis (BPS/IC)	
Panurethral strictures	198		
Aetiology and incidence	198	<i>Mariangela Mancini, Dick Janssen, Alessandro Morlacco, Enrico Ammirati, and Alessandro Giammo</i>	
Diagnosis	198	Introduction	229
Treatment options	198	Definition	229
Strictures post treatment (for other diseases)	198	Incidence	230
Post-radical prostatectomy and TURP	198	Diagnosis and the delayed diagnosis/misdiagnosis problem	230
Major reconstruction for recurrent cases; open, laparoscopic, and robotic management	199	Patient history	233

23. Expertise Area 3.2: Testicular cancer

Arnout Alberts, Tomas Buchler, Yue Che, Ana Fröbe, Marija Miletić, and Tahlita Zuiverloon

Serum tumour markers in testicular germ cell tumours	269
Alpha-fetoprotein	269
Chorionic gonadotropin, beta subunit	269
Lactate dehydrogenase	270
miR-371a-3p	270
Circulating free DNA	270
Management of postchemotherapy residual tumour masses and operative management in complex cases	270
Seminoma	270
Nonseminomatous germ cell tumour (NSGCT)	271
Surgical approach	271
Testicular cancer survivorship	272
Management of chemotherapy complications and delays	273
Neutropenia	273
Nausea and vomiting	274
Polyneuropathy	274
Pulmonary toxicity	274
Nephrotoxicity	274
Thrombosis and embolism	275
Long-term complications	275
Delays and interruptions in chemotherapy	275
References	276

24. Expertise Area 3.3: Adrenal cancer

Johan Langenhuijsen, Marija Miletić, Mirsala Solak, Mario Dominguez Esteban, Mariangela Mancini, Daphne Hompes, Tomislav Kulis, Jörg Fuchs, Bastian Amend, and Ana Fröbe

Introduction	281
Clinical presentation and examination	281
Diagnostic work-up in adrenal incidentaloma	282
Radiological work-up—Benign vs malignant	283
Biochemical work-up—Nonfunctional vs functional	283
Surgical approach	284
Laparoscopy and robotics	284
Open surgery	286
Lymph node dissection	286
Metastatic disease and local recurrence	287

Systemic treatment and adjuvant therapy	288
Adjuvant therapy	289
Acknowledgement	289
References	290

25. Expertise Area 3.4: Abdominopelvic sarcoma

Mariangela Mancini

Definition and epidemiology	295
Anatomical complexity of the retroperitoneum and the subperitoneal space	295
Histopathological classification of RPS and pelvic sarcomas	296
Liposarcomas	296
Leiomyosarcomas	297
Other less frequent forms	297
Differential diagnosis	297
Clinical presentation	298
Diagnostic roadmap	299
Staging	299
Need for biopsy	299
Treatment	300
General principles of treatment of RPS or subperitoneal sarcomas	300
Defining a treatment plan for each patient	300
Anatomical key points in the evaluation of an RPS or a subperitoneal sarcoma: Focus on assessment of tumour surgical resectability	300
Resectability and preoperative treatment (neoadjuvant approach)	300
Preoperative radiation	302
Intensity-modulated radiation therapy	302
Synchronous chemo-radiation	302
Neoadjuvant chemotherapy	303
With regional hyperthermia	303
Surgical resection of RPS or subperitoneal sarcomas with curative intent: Surgical key points and technical challenges	303
When surgical resectability seems not possible	304
Intraoperative radiation therapy	304
The role of adjuvant treatment: General principles	304
Prognostic factors	306
Outcomes	306
Guidelines from expert groups	306

Clinical follow-up and the COVID-19 pandemic era	306	Circumstances of diagnosis	313
Management of locally recurrent retroperitoneal or subperitoneal sarcomas	307	Imaging	313
Surgical treatment of recurrent disease	307	Biological evaluation	314
Preoperative therapy in case of recurrent disease	308	Genetic predisposition to renal tumours in children	314
Postoperative therapy in case of recurrent disease	308	Role of biopsy	315
Follow-up or recurrent disease	308	Malignant renal tumours	315
Consensus-based treatment recommendations currently available	308	Nephroblastoma or Wilms' tumour (WT)	315
Guidelines currently in use for clinical management of abdominopelvic sarcoma (English language)	310	Clear cell sarcoma of the kidney	319
References	310	Rhabdoid tumour	319
		Congenital mesoblastic nephroma or Bolande's tumour	319
26. Expertise Area 3.5: Rare renal tumour surgery		Renal cell carcinoma	319
<i>Matthieu Peycelon, Pascale Philippe-Chomette, Anne-Françoise Spinoit, and Marie Andersson</i>		Other malignant renal tumours	319
		Benign tumours	320
Introduction	313	Angiomyolipoma	320
General considerations	313	Pseudotumours	320
		Benign stromal tumours	320
		Others	321
		Long-term outcomes	321
		Conclusions	322
		References	322
		Index	327